Tag Archives: transcatheter aortic valve replacement

valve_in_valve-compressor

Valve-in-Valve Shows Good Evolution after 2 Years

Valve-in-Valve Shows Good Evolution after 2 Years

The degeneration of bioprostheses in aortic position occurs at approximately after 10 to 15 years. In this scenario, the treatment of choice used to be redo surgery, but with the evolution of transcatheter aortic valve replacement (TAVR), it became a valid alternative with a level IIa B evidence. While there are currently multiple analyses of

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

SURTAVI at 5 Years

Transcatheter aortic valve replacement (TAVR) by transfemoral access has shown great benefit for different risk groups, but its long-term durability is still uncertain. Available evidence comes from small analysis and a single randomized trial with 280 patients and an 8 year follow-up: the NOTION Trial, where TAVR showed less valvular degeneration than aortic valve replacement (AVR) surgery.

TCT 2022

TCT 2022 | PROTECTED TAVR

Stroke is still a major complication of transcatheter aortic valve replacement (TAVR), with a 30-day mortality of 16.7%. Even in the absence of symptoms, most patients (68-93%) have some type of diffusion imaging defect after TAVR implantation. The Sentinel cerebral protection device (CPD) (Boston Scientific) received FDA approval for the capture of emboligenic material that

La clave para tratar strokes: saber cuando detenerse

Should We Treat Stroke Percutaneously in TAVR?

Since its inception, transcatheter aortic valve replacement (TAVR) has improved greatly. However, there still are five big challenges to be solved: paravalvular leak, conduction disturbances, debilitating stroke, impaired kidney function, and major vascular complications and bleeding. Most cases of stroke are periprocedural and ischemic. So far, they have not been well analyzed in terms of

¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

TAVR in Bicuspid Patients: Are Outcomes the Same in Men and Women?

Bicuspid aortic valve stenosis (BAV) has not yet been analyzed in large, randomized studies, and TAVR in this scenario has been assessed only by small fairly studies. However, the information available is quite promising.   TAVR in women generally presents more complications than in men, but severe bicuspid aortic valve stenosis receiving TAVR has not been

Webinar SOLACI@Medtronic@CITIC | IV Summit TAVI Minimalista

IV Summit Minimalist TAVI – Step by Step: How to Streamline procedures?”

Next August 30 and 31 at 7:30 p.m. (Argentina / Brazil time) we will hold a new open event in conjunction with CITIC and with the support of Medtronic on how to optimize TAVI procedures. This scientific activity will feature prestigious specialists from many parts of the world and is entitled “IV Summit Minimalist TAVI

valve_in_valve-compressor

Surgical Bioprosthesis Deterioration: Is the Valve-in-Valve Technique a Good Option?

The use of surgical bioprostheses has significantly increased, and while they last 15 years or more, in cases where they fail (usually due to stenosis), the decision-making process is challenging. Transcatheter aortic valve replacement (TAVR) is a good alternative for this situation, although information on the subject matter is still scarce. Currently, the only available

tavi vs cirugia partner i

Non-Cardiac Surgery After TAVR Is Safe

There are increasingly more patients who have undergone transcatheter aortic valve replacement (TAVR) and require a non-cardiac intervention, or patients with other diseases who need surgery and are diagnosed with aortic stenosis.  In addition, on many occasions, surgery must be performed as soon as possible (as in cases of cancer) or is an emergency procedure.

The Best of Main Arena - SOLACI-SOCIME 2022

The Best of the SOLACI-SOCIME 2022 Main Arena: Structural—Selected Topics of TAVR

On the last session from day 1 of SOLACI-SOCIME 2022 on structural pathology, Dr. Raj Makkar, an international expert on the subject, talked about transcatheter aortic valve replacement (TAVR) in pure aortic regurgitation (AR), which presents several implantation challenges, such as insufficient anchoring, embolization, residual regurgitation, ring rupture, etc.  As opposed to patients with aortic

The Best of Main Arena - SOLACI-SOCIME 2022

The Best of the Main Arena at SOLACI-SOCIME 2022: TAVR Complex Anatomy

In the transcatheter aortic valve replacement (TAVR) session we had a presentation by Dr. John P. Vavalle (USA), head of the Structural Heart Disease Program at the University of North Carolina at Chapel Hill.  In his presentation, he showed how far the limits of percutaneous aortic valve implantation can be stretched by briefly showing successful

Top